A comparative study of panipenem/betamipron and imipenem/cilastatin in respiratory tract infections

Kohei Hara; Shigeru Kohno; Hironobu Koga; Kazuo Takebe; Masashi Tamura; Kazuki Konishi; Akiho Ohara; Masafumi Masuda; Takashi Tsuruya; Kazuyasu Abe; Tamotsu Takishima; Yasuo Tanno; Akira Watanabe; Masakichi Motomiya; Shigeo Takizawa; Nobuki Aoki; Izumi Hayashi; Kaoru Shimada; Junzaburo Kabe; Kouichiro Kudou; Kouichiro Nakata; Tatsuo Nakatani; Kohya Shiba; Hiroyuki Kobayashi; Shin Kawai; Fumio Matsumoto; Takeo Imai; Shigeki Odagiri; Masanori Matsumura; Kou Murohashi; Kaneo Suzuki; Hiroshi Takahashi; Takashi Sakuma; Noboru Syouji; Atsuhiko Sato; Masatoshi Iwata; Kaoru Shimokata; Hiroshi Saito; Takanao Murate; Hidetaka Kawatsu; Toshihiko Takeuchi; Yoshimitsu Hayashi; Hidekazu Hanaki; Masahito Kato; Jyouichi Kato; Ikuji Usami; Fumiyuki Kuze; Ryoichi Amitani; Fumio Miki; Kazuya Higashino; Shinsuke Tamura; Yasuko Hyodo; Midori Mikami; Takahiro Tsutsui; Hitoshi Yoshida; Shigeki Shibamoto; Takashi Sonoda; Naoki Togawa; Rinzo Soejima; Tsuyoshi Ogura; Fumitaka Ogushi; Michio Yamakido; Kenji Hasegawa; Takao Sasaki; Yuji Sugimoto; Yoshiro Sawae; Nobuyuki Shimono; Atsushi Shinoda; Tsuneo Ishibashi; Masayoshi Takamoto; Akira Kajiki; Yoshiya Kitahara; Hozumi Yamada; Osamu Katoh; Keizo Matsumoto; Atsushi Takahashi; Masaru Nasu; Yoichiro Goto; Atsushi Saito; Mitsuyoshi Nakashima; Keizo Yamaguchi; Mitsuo Kaku; Kazuyuki Sugawara

doi:10.11250/chemotherapy1953.40.613

A comparative study of panipenem/betamipron and imipenem/cilastatin in respiratory tract infections

Kohei Hara, Shigeru Kohno, Hironobu Koga, Kazuo Takebe, Masashi Tamura, Kazuki Konishi, Akiho Ohara, Masafumi Masuda, Takashi Tsuruya, Kazuyasu Abe, Tamotsu Takishima, Yasuo Tanno, Akira Watanabe, Masakichi Motomiya, Shigeo Takizawa, Nobuki Aoki, Izumi Hayashi, Kaoru Shimada, Junzaburo Kabe, Kouichiro KudouKouichiro Nakata, Tatsuo Nakatani, Kohya Shiba, Hiroyuki Kobayashi, Shin Kawai, Fumio Matsumoto, Takeo Imai, Shigeki Odagiri, Masanori Matsumura, Kou Murohashi, Kaneo Suzuki, Hiroshi Takahashi, Takashi Sakuma, Noboru Syouji, Atsuhiko Sato, Masatoshi Iwata, Kaoru Shimokata, Hiroshi Saito, Takanao Murate, Hidetaka Kawatsu, Toshihiko Takeuchi, Yoshimitsu Hayashi, Hidekazu Hanaki, Masahito Kato, Jyouichi Kato, Ikuji Usami, Fumiyuki Kuze, Ryoichi Amitani, Fumio Miki, Kazuya Higashino, Shinsuke Tamura, Yasuko Hyodo, Midori Mikami, Takahiro Tsutsui, Hitoshi Yoshida, Shigeki Shibamoto, Takashi Sonoda, Naoki Togawa, Rinzo Soejima, Tsuyoshi Ogura, Fumitaka Ogushi, Michio Yamakido, Kenji Hasegawa, Takao Sasaki, Yuji Sugimoto, Yoshiro Sawae, Nobuyuki Shimono, Atsushi Shinoda, Tsuneo Ishibashi, Masayoshi Takamoto, Akira Kajiki, Yoshiya Kitahara, Hozumi Yamada, Osamu Katoh, Keizo Matsumoto, Atsushi Takahashi, Masaru Nasu, Yoichiro Goto, Atsushi Saito, Mitsuyoshi Nakashima, Keizo Yamaguchi, Mitsuo Kaku, Kazuyuki Sugawara

General Internal Medicine

Research output: Contribution to journal › Article › peer-review

10 Citations (Scopus)

Abstract

With the aim of objectively evaluating the efficacy, safety and usefulness of panipenem/betamipron (PAPM/BP) in the treatment of chronic respiratory tract infection, a comparative study using imipenem/cilastatin sodium (IPM/CS) as the control drug was undertaken, and the following results obtained. Either PAPM/BP or IPM/CS, in a dose of 1.0 g/1.0 g daily (in 2 divided doses), was administered for a duration of, in principle, 14 days. 1) Clinical efficacy: The efficacy rate in the judgement of the committee was 81.3% in the PAPM/BP group and 81.7% in the IPM/CS group, with no significant difference between the two groups. Judged by the physician in charge, the rate was 84.0% in the PAPM/BP group and 87.3% in the IPM/CS group, with no significant difference between the two groups. 2) Bacteriological efficacy: The eradication rate was 76.7% in the PAPM/BP group and 74.4% in the IPM/CS group, with no significant difference between the two groups. 3) Side effects and abnormal laboratory data: The incidence of side effects was 2.5% in the PAPM/BP group and 5.1% in the IPM/CS group. Abnormal laboratory data were found in 28.8% and 29.0% respectively, but none was serious and no significant difference was seen between the two groups. 4) Usefulness: The rate of usefulness was evaluated by the committee to be 80.0% in the PAPM/BP group and 78.9% in the IPM/CS group, with no significant difference between the two groups. Judged by the physician in charge, the rate was 81.3% in the PAPM/BP group and 84.5% in the IPM/CS group, with no significant difference between the two groups. These results confirm that the administration of PAPM/BP, 1.0 g/1.0 g daily in the treatment of chronic respiratory tract infection is as clinically useful as the administration of IPM/CS, 1.0 g/1.0 g daily.

Original language	English
Pages (from-to)	613-637
Number of pages	25
Journal	Chemotherapy
Volume	40
Issue number	5
DOIs	https://doi.org/10.11250/chemotherapy1953.40.613
Publication status	Published - May 1992

All Science Journal Classification (ASJC) codes

Pharmacology (medical)
Infectious Diseases
Pharmacology
Drug Discovery
Oncology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.11250/chemotherapy1953.40.613

Cite this

Hara, K., Kohno, S., Koga, H., Takebe, K., Tamura, M., Konishi, K., Ohara, A., Masuda, M., Tsuruya, T., Abe, K., Takishima, T., Tanno, Y., Watanabe, A., Motomiya, M., Takizawa, S., Aoki, N., Hayashi, I., Shimada, K., Kabe, J., ... Sugawara, K. (1992). A comparative study of panipenem/betamipron and imipenem/cilastatin in respiratory tract infections. Chemotherapy, 40(5), 613-637. https://doi.org/10.11250/chemotherapy1953.40.613

Hara, K, Kohno, S, Koga, H, Takebe, K, Tamura, M, Konishi, K, Ohara, A, Masuda, M, Tsuruya, T, Abe, K, Takishima, T, Tanno, Y, Watanabe, A, Motomiya, M, Takizawa, S, Aoki, N, Hayashi, I, Shimada, K, Kabe, J, Kudou, K, Nakata, K, Nakatani, T, Shiba, K, Kobayashi, H, Kawai, S, Matsumoto, F, Imai, T, Odagiri, S, Matsumura, M, Murohashi, K, Suzuki, K, Takahashi, H, Sakuma, T, Syouji, N, Sato, A, Iwata, M, Shimokata, K, Saito, H, Murate, T, Kawatsu, H, Takeuchi, T, Hayashi, Y, Hanaki, H, Kato, M, Kato, J, Usami, I, Kuze, F, Amitani, R, Miki, F, Higashino, K, Tamura, S, Hyodo, Y, Mikami, M, Tsutsui, T, Yoshida, H, Shibamoto, S, Sonoda, T, Togawa, N, Soejima, R, Ogura, T, Ogushi, F, Yamakido, M, Hasegawa, K, Sasaki, T, Sugimoto, Y, Sawae, Y, Shimono, N, Shinoda, A, Ishibashi, T, Takamoto, M, Kajiki, A, Kitahara, Y, Yamada, H, Katoh, O, Matsumoto, K, Takahashi, A, Nasu, M, Goto, Y, Saito, A, Nakashima, M, Yamaguchi, K, Kaku, M & Sugawara, K 1992, 'A comparative study of panipenem/betamipron and imipenem/cilastatin in respiratory tract infections', Chemotherapy, vol. 40, no. 5, pp. 613-637. https://doi.org/10.11250/chemotherapy1953.40.613

@article{40648ae9c2374796a8aba6d4a4ce07b3,

title = "A comparative study of panipenem/betamipron and imipenem/cilastatin in respiratory tract infections",

abstract = "With the aim of objectively evaluating the efficacy, safety and usefulness of panipenem/betamipron (PAPM/BP) in the treatment of chronic respiratory tract infection, a comparative study using imipenem/cilastatin sodium (IPM/CS) as the control drug was undertaken, and the following results obtained. Either PAPM/BP or IPM/CS, in a dose of 1.0 g/1.0 g daily (in 2 divided doses), was administered for a duration of, in principle, 14 days. 1) Clinical efficacy: The efficacy rate in the judgement of the committee was 81.3% in the PAPM/BP group and 81.7% in the IPM/CS group, with no significant difference between the two groups. Judged by the physician in charge, the rate was 84.0% in the PAPM/BP group and 87.3% in the IPM/CS group, with no significant difference between the two groups. 2) Bacteriological efficacy: The eradication rate was 76.7% in the PAPM/BP group and 74.4% in the IPM/CS group, with no significant difference between the two groups. 3) Side effects and abnormal laboratory data: The incidence of side effects was 2.5% in the PAPM/BP group and 5.1% in the IPM/CS group. Abnormal laboratory data were found in 28.8% and 29.0% respectively, but none was serious and no significant difference was seen between the two groups. 4) Usefulness: The rate of usefulness was evaluated by the committee to be 80.0% in the PAPM/BP group and 78.9% in the IPM/CS group, with no significant difference between the two groups. Judged by the physician in charge, the rate was 81.3% in the PAPM/BP group and 84.5% in the IPM/CS group, with no significant difference between the two groups. These results confirm that the administration of PAPM/BP, 1.0 g/1.0 g daily in the treatment of chronic respiratory tract infection is as clinically useful as the administration of IPM/CS, 1.0 g/1.0 g daily.",

author = "Kohei Hara and Shigeru Kohno and Hironobu Koga and Kazuo Takebe and Masashi Tamura and Kazuki Konishi and Akiho Ohara and Masafumi Masuda and Takashi Tsuruya and Kazuyasu Abe and Tamotsu Takishima and Yasuo Tanno and Akira Watanabe and Masakichi Motomiya and Shigeo Takizawa and Nobuki Aoki and Izumi Hayashi and Kaoru Shimada and Junzaburo Kabe and Kouichiro Kudou and Kouichiro Nakata and Tatsuo Nakatani and Kohya Shiba and Hiroyuki Kobayashi and Shin Kawai and Fumio Matsumoto and Takeo Imai and Shigeki Odagiri and Masanori Matsumura and Kou Murohashi and Kaneo Suzuki and Hiroshi Takahashi and Takashi Sakuma and Noboru Syouji and Atsuhiko Sato and Masatoshi Iwata and Kaoru Shimokata and Hiroshi Saito and Takanao Murate and Hidetaka Kawatsu and Toshihiko Takeuchi and Yoshimitsu Hayashi and Hidekazu Hanaki and Masahito Kato and Jyouichi Kato and Ikuji Usami and Fumiyuki Kuze and Ryoichi Amitani and Fumio Miki and Kazuya Higashino and Shinsuke Tamura and Yasuko Hyodo and Midori Mikami and Takahiro Tsutsui and Hitoshi Yoshida and Shigeki Shibamoto and Takashi Sonoda and Naoki Togawa and Rinzo Soejima and Tsuyoshi Ogura and Fumitaka Ogushi and Michio Yamakido and Kenji Hasegawa and Takao Sasaki and Yuji Sugimoto and Yoshiro Sawae and Nobuyuki Shimono and Atsushi Shinoda and Tsuneo Ishibashi and Masayoshi Takamoto and Akira Kajiki and Yoshiya Kitahara and Hozumi Yamada and Osamu Katoh and Keizo Matsumoto and Atsushi Takahashi and Masaru Nasu and Yoichiro Goto and Atsushi Saito and Mitsuyoshi Nakashima and Keizo Yamaguchi and Mitsuo Kaku and Kazuyuki Sugawara",

year = "1992",

month = may,

doi = "10.11250/chemotherapy1953.40.613",

language = "English",

volume = "40",

pages = "613--637",

journal = "Chemotherapy",

issn = "0009-3165",

number = "5",

}

TY - JOUR

T1 - A comparative study of panipenem/betamipron and imipenem/cilastatin in respiratory tract infections

AU - Hara, Kohei

AU - Kohno, Shigeru

AU - Koga, Hironobu

AU - Takebe, Kazuo

AU - Tamura, Masashi

AU - Konishi, Kazuki

AU - Ohara, Akiho

AU - Masuda, Masafumi

AU - Tsuruya, Takashi

AU - Abe, Kazuyasu

AU - Takishima, Tamotsu

AU - Tanno, Yasuo

AU - Watanabe, Akira

AU - Motomiya, Masakichi

AU - Takizawa, Shigeo

AU - Aoki, Nobuki

AU - Hayashi, Izumi

AU - Shimada, Kaoru

AU - Kabe, Junzaburo

AU - Kudou, Kouichiro

AU - Nakata, Kouichiro

AU - Nakatani, Tatsuo

AU - Shiba, Kohya

AU - Kobayashi, Hiroyuki

AU - Kawai, Shin

AU - Matsumoto, Fumio

AU - Imai, Takeo

AU - Odagiri, Shigeki

AU - Matsumura, Masanori

AU - Murohashi, Kou

AU - Suzuki, Kaneo

AU - Takahashi, Hiroshi

AU - Sakuma, Takashi

AU - Syouji, Noboru

AU - Sato, Atsuhiko

AU - Iwata, Masatoshi

AU - Shimokata, Kaoru

AU - Saito, Hiroshi

AU - Murate, Takanao

AU - Kawatsu, Hidetaka

AU - Takeuchi, Toshihiko

AU - Hayashi, Yoshimitsu

AU - Hanaki, Hidekazu

AU - Kato, Masahito

AU - Kato, Jyouichi

AU - Usami, Ikuji

AU - Kuze, Fumiyuki

AU - Amitani, Ryoichi

AU - Miki, Fumio

AU - Higashino, Kazuya

AU - Tamura, Shinsuke

AU - Hyodo, Yasuko

AU - Mikami, Midori

AU - Tsutsui, Takahiro

AU - Yoshida, Hitoshi

AU - Shibamoto, Shigeki

AU - Sonoda, Takashi

AU - Togawa, Naoki

AU - Soejima, Rinzo

AU - Ogura, Tsuyoshi

AU - Ogushi, Fumitaka

AU - Yamakido, Michio

AU - Hasegawa, Kenji

AU - Sasaki, Takao

AU - Sugimoto, Yuji

AU - Sawae, Yoshiro

AU - Shimono, Nobuyuki

AU - Shinoda, Atsushi

AU - Ishibashi, Tsuneo

AU - Takamoto, Masayoshi

AU - Kajiki, Akira

AU - Kitahara, Yoshiya

AU - Yamada, Hozumi

AU - Katoh, Osamu

AU - Matsumoto, Keizo

AU - Takahashi, Atsushi

AU - Nasu, Masaru

AU - Goto, Yoichiro

AU - Saito, Atsushi

AU - Nakashima, Mitsuyoshi

AU - Yamaguchi, Keizo

AU - Kaku, Mitsuo

AU - Sugawara, Kazuyuki

PY - 1992/5

Y1 - 1992/5

N2 - With the aim of objectively evaluating the efficacy, safety and usefulness of panipenem/betamipron (PAPM/BP) in the treatment of chronic respiratory tract infection, a comparative study using imipenem/cilastatin sodium (IPM/CS) as the control drug was undertaken, and the following results obtained. Either PAPM/BP or IPM/CS, in a dose of 1.0 g/1.0 g daily (in 2 divided doses), was administered for a duration of, in principle, 14 days. 1) Clinical efficacy: The efficacy rate in the judgement of the committee was 81.3% in the PAPM/BP group and 81.7% in the IPM/CS group, with no significant difference between the two groups. Judged by the physician in charge, the rate was 84.0% in the PAPM/BP group and 87.3% in the IPM/CS group, with no significant difference between the two groups. 2) Bacteriological efficacy: The eradication rate was 76.7% in the PAPM/BP group and 74.4% in the IPM/CS group, with no significant difference between the two groups. 3) Side effects and abnormal laboratory data: The incidence of side effects was 2.5% in the PAPM/BP group and 5.1% in the IPM/CS group. Abnormal laboratory data were found in 28.8% and 29.0% respectively, but none was serious and no significant difference was seen between the two groups. 4) Usefulness: The rate of usefulness was evaluated by the committee to be 80.0% in the PAPM/BP group and 78.9% in the IPM/CS group, with no significant difference between the two groups. Judged by the physician in charge, the rate was 81.3% in the PAPM/BP group and 84.5% in the IPM/CS group, with no significant difference between the two groups. These results confirm that the administration of PAPM/BP, 1.0 g/1.0 g daily in the treatment of chronic respiratory tract infection is as clinically useful as the administration of IPM/CS, 1.0 g/1.0 g daily.

AB - With the aim of objectively evaluating the efficacy, safety and usefulness of panipenem/betamipron (PAPM/BP) in the treatment of chronic respiratory tract infection, a comparative study using imipenem/cilastatin sodium (IPM/CS) as the control drug was undertaken, and the following results obtained. Either PAPM/BP or IPM/CS, in a dose of 1.0 g/1.0 g daily (in 2 divided doses), was administered for a duration of, in principle, 14 days. 1) Clinical efficacy: The efficacy rate in the judgement of the committee was 81.3% in the PAPM/BP group and 81.7% in the IPM/CS group, with no significant difference between the two groups. Judged by the physician in charge, the rate was 84.0% in the PAPM/BP group and 87.3% in the IPM/CS group, with no significant difference between the two groups. 2) Bacteriological efficacy: The eradication rate was 76.7% in the PAPM/BP group and 74.4% in the IPM/CS group, with no significant difference between the two groups. 3) Side effects and abnormal laboratory data: The incidence of side effects was 2.5% in the PAPM/BP group and 5.1% in the IPM/CS group. Abnormal laboratory data were found in 28.8% and 29.0% respectively, but none was serious and no significant difference was seen between the two groups. 4) Usefulness: The rate of usefulness was evaluated by the committee to be 80.0% in the PAPM/BP group and 78.9% in the IPM/CS group, with no significant difference between the two groups. Judged by the physician in charge, the rate was 81.3% in the PAPM/BP group and 84.5% in the IPM/CS group, with no significant difference between the two groups. These results confirm that the administration of PAPM/BP, 1.0 g/1.0 g daily in the treatment of chronic respiratory tract infection is as clinically useful as the administration of IPM/CS, 1.0 g/1.0 g daily.

UR - http://www.scopus.com/inward/record.url?scp=0026780143&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026780143&partnerID=8YFLogxK

U2 - 10.11250/chemotherapy1953.40.613

DO - 10.11250/chemotherapy1953.40.613

M3 - Article

AN - SCOPUS:0026780143

SN - 0009-3165

VL - 40

SP - 613

EP - 637

JO - Chemotherapy

JF - Chemotherapy

IS - 5

ER -

A comparative study of panipenem/betamipron and imipenem/cilastatin in respiratory tract infections

Abstract

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this